Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Lung Neoplasms. Found 149 abstracts

no pagination
Steffen LE, Cheavens JS, Vowles KE, Gabbard J, Nguyen H, Gan GN, Edelman MJ, Smith BW. Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Feb;28(2):827-35.   PMCID: PMC6885110
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2019 Sep 28;381(21):2020-31.
Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, Nieva JJ, Spira AI, VanderWalde AM, Wozniak AJ, Kim ES, Liu SV. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019 Apr 15;25(16):4966-72.
Santerre M, Chatila W, Wang Y, Mukerjee R, Sawaya BE. HIV-1 Nef promotes cell proliferation and microRNA dysregulation in lung cells. Cell cycle (Georgetown, Tex). 2019 Jan;18(2):130-42.
Gettinger S, Hellmann MD, Chow LQ, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 Sep;13(9):1363-72.
Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and health. 2018 Aug;40:e2018040.   PMCID: PMC6232654
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJ, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate I. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017 Jun 22;376(25):2415-26.   PMCID: Comment
Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG, Deming R, Dixon JG, Burri SH, Chung C, Menard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2017 Aug 05;99(5):1173-8.   PMCID: PMC5699951
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology. 2017 Jul;35(19):2184-92.   PMCID: PMC5493050
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, Decamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2017 Apr;15(4):504-35.
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41.   PMCID: PMC5476941
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33.   PMCID: PMC6075826
Michael JV, Wurtzel JG, Mao GF, Rao AK, Kolpakov MA, Sabri A, Hoffman NE, Rajan S, Tomar D, Madesh M, Nieman MT, Yu J, Edelstein LC, Rowley JW, Weyrich AS, Goldfinger LE. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood. 2017 Aug 03;130(5):567-80.   PMCID: PMC5542851
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Aug;3(8):1051-8.   PMCID: PMC5650234
Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA, Miller KA, Steele VE, Miller MS, Clapper ML, O'Sullivan MG, Ondrey FG. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. Cancer prevention research (Philadelphia, Pa). 2017 Feb;10(2):116-23.   PMCID: PMC5690483
Vachani A, Wong YN, Israelite J, Mitra N, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW, Epstein AJ. Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care. 2017 Dec;55(12):e131-e136.
Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer [comment]. The New England journal of medicine. 2016 Feb 04;374(5):493-4.   PMCID: NA
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.
Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res. 2016 Jan 15;76(2):206-15.   PMCID: PMC4715907
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Lung Neoplasms

Lung Neoplasms Non-Small-Cell Lung Carcinoma Male Female pathology therapeutic use drug therapy metabolism Middle Aged Monoclonal Antibodies Survival Rate administration & dosage Antineoplastic Combined Chemotherapy Protocols adverse effects Aged genetics methods Antineoplastic Agents B7-H1 Antigen Cohort Studies mortality Prognosis etiology Treatment Outcome Disease-Free Survival Taxoids pharmacology MicroRNAs 80 and over Aged prevention & control Nivolumab statistics & numerical data Pemetrexed Mice Neoplasm Staging Adult Carboplatin Combined Modality Therapy Neoplasm Metastasis Registries Follow-Up Studies physiology Squamous Cell Carcinoma Drug Dose-Response Relationship therapy Immunotherapy biosynthesis Cell-Derived Microparticles Fatigue epidemiology Programmed death 1 axis inhibitor Reproducibility of Results Survival Analysis Gene Fusion Thiazolidinediones mitochondria Cisplatin Hope Proto-Oncogene Proteins p21(ras) Argonaute Proteins HIV-1 transplantation Lung cancer Asbestos Clinical Trials as Topic microRNA biogenesis Immunohistochemistry Molecular Pathology Veterans lung cancer Cross-Sectional Studies Dinoprostone Pain Prostatic Neoplasms Celecoxib Autophagy DEAD-box RNA Helicases Biological Assay Algorithms Epidermal Growth Factor Receptor Brain Neoplasms Colonic Neoplasms Adenocarcinoma Double-Blind Method HEK293 Cells Cell Survival Practice Guidelines as Topic Retrospective Studies Recombinant Proteins United States Pathologists immunology Androgen Antagonists Mesothelioma radiotherapy Transfection Androgen antagonists Biomarkers Neuregulin-1 Ribonuclease III chemically induced urine enzymology Ipilimumab CD274 Antigens Germ-Line Mutation Tumor Suppressor Proteins Neoplasm Proteins Genetic Predisposition to Disease Molecular Targeted Therapy Antibodies Monoclonal Antibodies-Humanized diagnosis Hormones Immunological Antineoplastic Agents Blood Platelets Erlotinib Hydrochloride secondary Cranial Irradiation A549 Cells Erlotinib Disease Management EGFR-mutant NSCLC Second Primary Neoplasms Recurrence Deoxycytidine Human Immunodeficiency Virus nef Gene Products Adjuvant Radiotherapy Cell Proliferation Lung neoplasms Combination therapy Prostatic neoplasms Missense Mutation Adenoma Fusion Oncogene Proteins Goal setting analogs & derivatives complications Electronic Health Records Mitochondria Palliative Human immunodeficiency virus (HIV) Radiosurgery HIV Infections Chemoprevention virology Risk Colorectal Neoplasms Proteinase-Activated Receptors NADH Dehydrogenase
Last updated on Saturday, July 04, 2020